National Spotlight Features Phio’s Innovative RNAi Technology Platform
MARLBOROUGH, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced its INTASYL platform will be the focus of Viewpoint, a national program hosted by Dennis Quaid. The program will air in April on PBS stations across the country.
- MARLBOROUGH, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced its INTASYL platform will be the focus of Viewpoint, a national program hosted by Dennis Quaid.
- The program will air in April on PBS stations across the country.
- The spotlight will also be featured nationally on Fox Business Network on April 24th, and regionally on a number of networks, including CNN and MSNBC, throughout the month of April.